Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
Full metadata record
|dc.identifier.citation||The Cochrane Database of Systematic Reviews, 2004; 2(CD00019):1-89||en|
|dc.description.abstract||BACKGROUND:Adding thyrotropin-releasing hormones (TRH) to corticosteroids has been suggested as a way of improving fetal lung development. OBJECTIVES:The objective of this review was to assess the effect of giving prenatal TRH in addition to corticosteroids to women at risk of very preterm birth for the prevention of neonatal respiratory disease. SEARCH STRATEGY:We searched the Cochrane Pregnancy and Childbirth Group trials register, Cochrane Controlled Trials Register, and bibliographies. Date of last search: January 1999. SELECTION CRITERIA:Randomised controlled trials in women at sufficient risk of preterm birth to warrant the use of prenatal corticosteroids to promote lung maturity. TRH and corticosteroids were compared with corticosteroids with or without placebo. The main outcomes considered were fetal and neonatal mortality, neonatal morbidity, childhood development and maternal morbidity. DATA COLLECTION AND ANALYSIS:All assessments of trial eligibility, quality and data extractions were done by at least two authors independently. MAIN RESULTS:Over 4500 women were recruited into the 11 included trials. Five trials were rated of high quality. Overall, prenatal TRH, in addition to corticosteroids, did not reduce the risk of neonatal respiratory disease, chronic oxygen dependance, or improve fetal, neonatal or childhood outcome in any of the outcomes assessed by intention-to-treat analyses. Indeed, the data showed prenatal TRH to have adverse effects for women and their infants. All side effects monitored were more likely to occur in women receiving TRH. In the infants, prenatal TRH increased the risk of infants needing ventilation (relative risk (RR) 1.16, 95% confidence interval (CI) 1.03-1.29), having a low Apgar score at five minutes (RR 1.80, 95% CI 1.14-1.92) and, for the one trial providing data, was associated with poorer outcomes at the 12 month follow up. Sensitivity analyses by trial quality, or subgroups with differing times from entry to delivery, or different dose regimens of TRH, did not change these findings. REVIEWER'S CONCLUSIONS:On the basis of currently available evidence, prenatal TRH, in addition to corticosteroids, given to women at risk of very preterm birth cannot be recommended for clinical practice.||en|
|dc.description.statementofresponsibility||Crowther CA, Alfirevic Z, Haslam RR||en|
|dc.publisher||Update Software Ltd||en|
|dc.subject||Humans; Respiratory Distress Syndrome, Newborn; Glucocorticoids; Pregnancy; Infant, Newborn; Infant, Premature; Female; Obstetric Labor, Premature; Thyrotropin-Releasing Hormone||en|
|dc.title||Thyrotropin-releasing hormone added to corticosteroids for women at risk of preterm birth for preventing neonatal respiratory disease||en|
|pubs.library.collection||Obstetrics and Gynaecology publications||en|
|dc.identifier.orcid||Crowther, C. [0000-0002-9079-4451]||en|
|Appears in Collections:||Obstetrics and Gynaecology publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.